MARKET

STML

STML

Stemline
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.03
0.00
0.00%
After Hours: 6.98 -0.05 -0.71% 16:49 01/17 EST
OPEN
7.14
PREV CLOSE
7.03
HIGH
7.39
LOW
6.94
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
18.22
52 WEEK LOW
6.01
MARKET CAP
351.57M
P/E (TTM)
-2.9107
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of STML and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

STML News

  • We're Hopeful That Stemline Therapeutics (NASDAQ:STML) Will Use Its Cash Wisely
  • Simply Wall St..10h ago
  • Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $14
  • Benzinga.4d ago
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.5d ago
  • Mid-Afternoon Market Update: Dow Turns Lower; Stemline Therapeutics Shares Plummet
  • Benzinga.6d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About STML

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
More

Webull offers Stemline Therapeutics Inc (STML) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.